• Users Online: 46
  • Home
  • Print this page
  • Email this page


 
 Table of Contents  
REVIEW
Year : 2018  |  Volume : 8  |  Issue : 3  |  Page : 111-115

Ozone therapy for diabetic foot


1 Department of Physiology and Biophysics, Stony Brook University School of Medicine, New York, NY, USA
2 Department of Physiology and Biophysics, Stony Brook University School of Medicine, New York, NY, USA; Medical Student Research Institute, St. George's University School of Medicine, Grenada, West Indies
3 Department of Internal Medicine, Stony Brook Southampton Hospital, Southampton, NY, USA
4 Foley Plaza Medical, New York, NY, USA
5 Department of Physiology and Biophysics; Department of Urology, Stony Brook University School of Medicine, New York, NY, USA

Date of Submission01-Jul-2018
Date of Acceptance03-Aug-2018
Date of Web Publication25-Sep-2018

Correspondence Address:
Sardar Ali Khan
Department of Physiology and Biophysics; Department of Urology, Stony Brook University School of Medicine, New York, NY
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2045-9912.241076

Rights and Permissions
  Abstract 

Diabetic foot ulcers (DFU) are a burden to the diabetic community. With increasing medical bills, to unsuccessful treatment, those suffering from DFUs can use alternative therapeutics. First seen in the mid-1800s, ozone (O3) is thought to be unstable, due to inherent molecular nature. With the help of pharmaceutical science, various O3 treatments have flourished in the medical community to help those suffering from DFUs. Promising results are seen through numerous studies. Usually, a mixture of both O2 and O3 is seen in pressurized machines as administered to the foot ulcer. Foot ulcers, specifically DFUs, need to be assessed, cleaned, and treated as fast as possible for the fastest results. Results such as amputation can be seen if the foot is not attended to as soon as possible. With fast growing clinical trials in O3 therapy and quick administration of the O3, O3 therapy may be on the rise to be at the forefront of treating DFUs. Compelling evidence is seen in clinical trials, but more must be done to fully understand the role of O3 in DFUs.

Keywords: ozone therapy; wound closure; oxygen-ozone; diabetic foot ulcer; diabetes mellitus; Charcot foot; peripheral arterial disease; wound healing


How to cite this article:
Kushmakov R, Gandhi J, Seyam O, Jiang W, Joshi G, Smith NL, Khan SA. Ozone therapy for diabetic foot. Med Gas Res 2018;8:111-5

How to cite this URL:
Kushmakov R, Gandhi J, Seyam O, Jiang W, Joshi G, Smith NL, Khan SA. Ozone therapy for diabetic foot. Med Gas Res [serial online] 2018 [cited 2018 Dec 11];8:111-5. Available from: http://www.medgasres.com/text.asp?2018/8/3/111/241076


  Introduction Top


Foot ulcers have an incidence of 4–10% in patients diagnosed with diabetes mellitus and a lifetime incidence of around 25%.[1] Furthermore, it is clear that patients that present diabetic foot ulcers (DFU) are hospitalized more often than without DFU. Amputations can be attributed to ischemia, infection, neuropathy, faulty wound healing, ulceration, gangrene, and initial minor trauma.[2] Recurrent infections in patients suffering from type 2 diabetes mellitus (T2DM) coupled with high plantar pressure are a major determining factor for DFUs.[3] Common treatments of DFU is debridement, offloading areas of friction and other conventional wound managements.[4] If treatment is delayed, the neuropathic and vascular complication of DFU can lead to gangrene or even amputation.[5] Not only is foot problems of diabetic patients seen as a major factor when considering morbidity, there seems to be a cost burden with heavy expenditure associated with treatment for the diabetic foot (DF).[6] The use of ozone (O3) within the medical community has begun in the mid 19th century.[7] Medicinal application of O3 is met with great discourse due to its inherently unstable nature. However, it is believed that O3 can be initiated to pharmaceutical science with great therapeutic benefit to specific biological systems and not just serve as an esoteric approach.[8] O3 has been seen to be used in many medicinal applications ranging from uses in dentistry to proper sterilization of medical instruments.[7],[9] Beneficial effects of O3 has been seen in orthopedics, mucosal and cutaneous infections.[10] Future effects can show O3 therapy being used to treat heart failure.[11] Furthermore, there is growing evidence that O3 can be used to treat DFUs. A study showed that O3 treatment via rectal insufflation can improve glycemic index along with preventing oxidative stress in diabetic rats.[12] Efficacy can be measured by how well the wound has closed in DFU after O3 treatment has been administered.[13] Herein we review the evidence for possible use of O3 therapy on DFU.


  Classification of Diabetic Foot Ulcers Top


There are several different ways to assess the severity of a DFU. The most common classification system surfaced in the 1970s named the Meggit-Wagner classification, summarized in [Table 1].[14] The Meggit-Wagner classification system has been around the longest, however, some researchers believe it lacks overall substance to describe the ischemia and possible complications. In the early 1990s a more profound classification system, developed by the University of Texas, surfaced and is summarized in [Table 2].[15] Although these two classification systems are both very much used today, it is believed that the Meggit-Wagner classification is too simple and the University of Texas classification is too complex. That is until Amit Jain proposed a new classification based on infective and non-infective complications as depicted in [Table 3].[16]
Table 1: Meggit-Wagner classification system for diabetic foot ulcer[14]

Click here to view
Table 2: University of Texas classification system for diabetic foot ulcer[15]

Click here to view
Table 3: Amit Jain's classification system for diabetic foot ulcer[16]

Click here to view



  Molecular Genetics of Diabetic Foot Ulcers Top


The Intelectin 1 (ITLN1) gene encodes a protein known as omentin. Inherently, omentin has endothelial vasodilator activity and anti-inflammatory actions.[17] For this reason, it is believed to be a protective factor in DFUs since they are vascular complications. Mrozikiewicz-Rakowska et al.[18] sought to evaluate the association of the allelic variant, rs2274907, of the ITLN gene and the occurrence of DF in patients diagnosed with T2DM. A study with 670 individuals was done; 204 individuals had T2DM with DF, 299 had T2DM with no signs of DF, and 167 individuals served as a healthy control. Mrozikiewicz-Rakowska et al.[18] found that neuropathy, ischemic heart disease, retinopathy, obesity, active smoking, and hyperlipidemia were all seen more frequently in patients with T2DM and DF than with T2DM and no DF. Furthermore, allele A of the rs2274907 variant was seen at a more frequent rate in the DF group than the healthy control. His team concluded the variant is associated with increased prevalence of DF.[18] He also found that allele A is sex-specific and is present in men. Therefore, men with single-nucleotide variants (SNV) are at risk for DF. Individuals present with DFU have overexpressed pro-inflammatory cytokines. The cytokines seen present are: tumor necrosis factor α (TNF-α), chemokines (e.g., CCL2), stromal cell-derived factor 1 (SDF-1), and interleukins (IL) 1 and 6.[19] Dhamodharan et al.[20] studied the role and genotyped IL-6 (rs1800795), TNF-α (rs1800629), and SDF-1 (rs361525) SNVs in DFU. This study showed that IL-6-174 CC and GC genotypes protected against diabetes, but not no association with DFU was found. TNF-α-308 AA and GA was correlated with increased susceptibility towards diabetes and DFU. SDF-1-801 AA and GA role was similar to that IL-6-184 CC and GC with protection against DFU as well. This was studied via serum levels of IL-6, TNF-α, and SDF-1 variants, along with other diabetogenic markers.[20]


  Diagnosis of Diabetic Foot Ulcers Top


Patients presented with DFUs are at risk for having peripheral arterial disease (PAD). Furthermore, nearly 50% of patients present with DFU are also present with PAD.[21] A common physical examination for diabetic patients with foot ulcers is the use of ankle brachial pressure-systolic (ABI-s). The use of the ABI-s test is to understand how severe PAD has advanced in patients with DFUs. However, diabetic patients tend to have calcified lower limb arteries, disrupting the systolic pressure in the arteries after the contraction of the heart. ABI-s can be falsely elevated due to the calcified lower limb arteries. A study shows that instead of performing ABI-s one can perform ankle brachial pressure-diastolic (ABI-d). Asbeutah et al.[22] had a size of 51 patients present with DFUs, 26 of which came present with calcified lower limbarteries and 25 of which did not present calcification. Another 25 persons were used as a control. Simply enough, both ABI-s and ABI-d were measured bilaterally via a brachial and ankle oscillometric pressure. The use of analysis of variance (ANOVA) showed statistical significance among people with the use of ABI-s and ABI-d leading to the conclusion that ABI-d may be a better tool for patients with DFUs with calcified arteries.[22] More studies have been done to see whether other forms of non-invasive vascular assessment can be performed to asses PAD more significantly. Common device-based diagnostic testing for patients with DFU and possible PAD includes color duplex ultrasonography, MR angiography, radiography, capillaroscopy, phlebography, continuous wave Doppler (CWD) and toe-brachial index (TBI).[23] Some researchers believe that ABI testing is not as effective as others such as CWD or TBI. A study was done where 117 participants were recruited with only 72 present with diabetes and 45 without diabetes. All patients received diagnostic testing via ABI, TBI, and CWD from the right lower limb. To properly assess accuracy a color duplex ultrasonography was used. Tehan et al.[24] determined that CWD was both the most sensitive and most specific in determining the presence PAD in patients with diabetes than TBI or ABI. Another study ruled out against ABI because of the significant limitation it places on diabetic patients presented with critical limb ischemia.[25]


  Applying Ozone to Diabetic Foot Ulcers Top
[Table 4]
Table 4: Studies testing ozone for diabetic wound care

Click here to view


A study demonstrated that ozonated water, along with ozonated oils, can be used as a disinfectant and healing stimulant.[10],[26] This can reap great benefit for individuals suffering from DFUs. Furthermore, O2–O3 treatment can improve vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), and platelet-derived growth factor (PDGF) levels.[27] The aforementioned growth factors, specifically, TGF-β, seem to increase in patients with DFUs and can heal the localized gangrene and tissue remodeling.[28],[29],[30] O3 causes platelets to aggregate, along with the release of the specific growth factors (e.g., PDGF, TGF-β, and IL-8) which is known to heal wounds rapidly.[28] Furthermore, O3, when applied to DFUs, eliminates pathogens and the O2 promotes proliferation of fibroblasts. This helps rebuild the intercellular matrix, healing the area around the DFU.[30] Bulynin et al.[31] demonstrated that O3 has antibacterial properties and developed a new method for treatment via hydropressive treatment of wounds. A stream of ozonized fluids is generated under a pressure of 350 ATM and an “OZh-2” apparatus is used. The wound is cleansed rapidly, reduces chance of infection, and period of treatment.[31] One study showed that the use of hyperbaric oxygen therapy can ameliorate dermal wound healing.[32] Travagli et al.[30] believe that the accelerated trend of wound closure in a young population may be due to O2 tension by O3 in the surrounding wound area that acts as an antibacterial substance to decrease bacterial infection. In the late 20th century, a team of German scientists used O3 on skin ulcers caused by diabetes. They used a polythene-bag for 25 minutes on average with a concentration ranging from 10 to 80 μg/mL. The different concentrations aforementioned were used with how severe the ulcers were. As the patients’ ulcers healed, a lower concentration of O3 was used.[33] Záhumenský et al.[34],[35] stated that offloading and debridement of the area around the DFU is a key step in beginning therapy for neuropathic ulceration. Furthermore, the healing process can be accelerated by O3, however, one should wear proper footwear to alleviate unnecessary pressure to the foot. In non-healing wounds, a combination of O2-O3 therapy might be of benefit. A study showed that it can heal and reduce the pain due to the inherent disinfectant properties and scavenging properties of endogenous oxygen free radicals.[36] O2-O3 is recognized as a disinfectant because it is known to inactivate bacteria by destroying their envelope through oxidation of specific proteins and lipids. Moreover, interferon, TNF, and IL-2 activate the immune system.[7],[36],[37] This can explain why a reduction in infection is seen when O3 therapy is used for DFUs. A few studies showed that when patients come present with orthopedic wounds, O3 therapy can be applied after initial conventional treatment.[38],[39]


  Safety of Ozone Therapy Top


The utility and safety of intralesional O3 injection in the treatment of chronic wounds has not yet been reliably assessed.[44] Though O3 therapy is typically safe without adverse reactions,[45] it may be toxic if administered outside its therapeutic window.[46] Because intralesional O3 injection has not yet been used in any of the studies involving DFUs, its safety has not yet been ascertained. These injections may inadvertently drive the superficial infection into the deeper tissue.[44] Moreover, O3 therapy is not recommended for deep, heavily infected or necrotic wounds.[35]

Uzun et al.[44] described a case of a diabetic patient who developed severe foot necrosis and infection after receiving intralesional O3 injections for a non-healing wound. Major complications that have been linked to O3 injections for lumbar disc herniation[45] include vitreo-retinal hemorrhages,[47] ventral and dorsal root injury,[48] vertebrobasilar stroke,[49] pyogenic discitis, and ventral epidural abscess,[50] and fulminant septicemia and death.[51] Skin irritation may follow topical O3 application while respiratory irritation may occur due to gas emitted from the generator.[35] In O2-O3therapy via autohemotransfusion for psoriasis, Marchetti et al.[52] described a fatal gas embolism.

When tested in pregnant rats, teratogenic or embriotoxic effects (i.e., fetal malformations) of O3 administered via rectal insufflation have not been identified.[53] In the end, to prove the inocuity of O3, more controlled clinical trials are warranted.


  Preventive Care Top


Common measures individual can take to prevent DFUs is to get an annual DF screening along with care intervention, especially those at high risk of DF complications.[54] Another measure, limited to individuals who have experienced ulceration, is nerve decompression surgery. It can prevent further ulceration along with amputation.[55] PAD is a major complication of DF and can determine the prognosis of healing. According to the Eurodiale study group, a neuropathic ulcer shift to neuro-ischemic ulcer is quite often. Assessing PAD via imaging and revascularization can dramatically reduce health risks if treated appropriately and on time.[56] Diabetic neuropathic ulcers can be managed by removing calluses, controlling infection, and reducing the amount of weight placed on the afflicted foot.[57] Many physicians agree that one of the greatest ways to decrease rates of mortality and morbidity among those who suffer from DF complications is early recognition.[58] Holistic care is available across the world via Multi-Disciplinary Foot Clinics.[59] Callus formation in DF patients serves a high level of predictability of ulcer formation. One can remove such calluses via urea-based preparations.[60] It behooves patients to consider preventative measures because a study has showed individuals with DFUs have a poor health-related quality of life.[61]


  Conclusion Top


The purpose of this review is to provide the scientific community with up-to-date clinical trials, peer-reviewed studies, and compelling evidence on O3 therapy in the treatment of DFUs. Further studies with a larger sample size would corroborate existing evidence.

 
  References Top

1.
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217-228.  Back to cited text no. 1
    
2.
Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990;13:513-521.  Back to cited text no. 2
    
3.
Viswanathan V, Snehalatha C, Sivagami M, Seena R, Ramachandran A. Association of limited joint mobility and high plantar pressure in diabetic foot ulceration in Asian Indians. Diabetes Res Clin Pract. 2003;60:57-61.  Back to cited text no. 3
    
4.
Downey-Carmona FJ, González-Herranz P, De La Fuente-González C, Castro M. Acute compartment syndrome of the foot caused by a hemangioma. J Foot Ankle Surg. 2006;45:52-55.  Back to cited text no. 4
    
5.
Armstrong DG, Lipsky BA. Advances in the treatment of diabetic foot infections. Diabetes Technol Ther. 2004;6:167-177.  Back to cited text no. 5
    
6.
Shobhana R, Rao PR, Lavanya A, Vijay V, Ramachandran A. Foot care economics--cost burden to diabetic patients with foot complications: a study from southern India. J Assoc Physicians India. 2001;49:530-533.  Back to cited text no. 6
    
7.
Elvis AM, Ekta JS. Ozone therapy: A clinical review. J Nat Sci Biol Med. 2011;2:66-70.  Back to cited text no. 7
    
8.
Zanardi I, Borrelli E, Valacchi G, Travagli V, Bocci V. Ozone: A Multifaceted Molecule with Unexpected Therapeutic Activity. Curr Med Chem. 2016;23:304-314.  Back to cited text no. 8
    
9.
Azarpazhooh A, Limeback H. The application of ozone in dentistry: a systematic review of literature. J Dent. 2008;36:104-116.  Back to cited text no. 9
    
10.
Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. 2009;29:646-682.  Back to cited text no. 10
    
11.
Buyuklu M, Kandemir FM, Set T, et al. Beneficial Effects of Ozone Therapy on Oxidative Stress, Cardiac Functions and Clinical Findings in Patients with Heart Failure Reduced Ejection Fraction. Cardiovasc Toxicol. 2017;17:426-433.  Back to cited text no. 11
    
12.
Al-Dalain SM, Martínez G, Candelario-Jalil E, et al. Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats. Pharmacol Res. 2001;44:391-396.  Back to cited text no. 12
    
13.
Wainstein J, Feldbrin Z, Boaz M, Harman-Boehm I. Efficacy of ozone-oxygen therapy for the treatment of diabetic foot ulcers. Diabetes Technol Ther. 2011;13:1255-1260.  Back to cited text no. 13
    
14.
Zakaria Z, Afifi M, Sharifudin MA. Clinical Factors affecting Minor Amputation in Diabetic Foot Disease at Tengku Ampuan Afzan Hospital, Kuantan. Malays J Med Sci. 2015;22:41-47.  Back to cited text no. 14
    
15.
Levin ME, O’Neal LW, Bowker JH, Pfeifer MJ. Levin and O’Neals the diabetic foot. Philadelphia: Mosby/Elsevier; 2008.  Back to cited text no. 15
    
16.
Jain AKC, Ahmeti I, Bogoev M, et al. A new classification of diabetic foot complications: a simple and effective teaching tool. J Diab Foot Comp. 2012;4:1-5.  Back to cited text no. 16
    
17.
Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010;393:668-672.  Back to cited text no. 17
    
18.
Mrozikiewicz-Rakowska B, Sobczyk-Kopcioł A, Szymański K, et al. Role of the rs2274907 allelic variant of the ITLN1 gene in patients with diabetic foot. Pol Arch Intern Med. 2017;127:319-327.  Back to cited text no. 18
    
19.
Viswanathan V. Role of molecular genetics in diabetic foot ulcer. Pol Arch Intern Med. 2017;127:310-311.  Back to cited text no. 19
    
20.
Dhamodharan U, Viswanathan V, Krishnamoorthy E, Rajaram R, Aravindhan V. Genetic association of IL-6, TNF-α and SDF-1 polymorphisms with serum cytokine levels in diabetic foot ulcer. Gene. 2015;565:62-67.  Back to cited text no. 20
    
21.
Brownrigg JR, Schaper NC, Hinchliffe RJ. Diagnosis and assessment of peripheral arterial disease in the diabetic foot. Diabet Med. 2015;32:738-747.  Back to cited text no. 21
    
22.
Asbeutah AM, AlMajran AA, Asfar SK. Diastolic versus systolic ankle-brachial pressure index using ultrasound imaging & automated oscillometric measurement in diabetic patients with calcified and non-calcified lower limb arteries. BMC Cardiovasc Disord. 2016;16:202.  Back to cited text no. 22
    
23.
Spoljar S. List of diagnostic tests and procedures in leg ulcer. Acta Med Croatica. 2013;67 Suppl 1:21-28.  Back to cited text no. 23
    
24.
Tehan PE, Bray A, Chuter VH. Non-invasive vascular assessment in the foot with diabetes: sensitivity and specificity of the ankle brachial index, toe brachial index and continuous wave Doppler for detecting peripheral arterial disease. J Diabetes Complications. 2016;30:155-160.  Back to cited text no. 24
    
25.
Pardo M, Alcaraz M, Bernal FL, et al. A solution to ankle-brachial index limitations in peripheral transluminal angioplasty. Radiol Med. 2013;118:1373-1378.  Back to cited text no. 25
    
26.
Bocci V, Zanardi I, Huijberts MS, Travagli V. Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. Diabetes Metab Syndr. 2011;5:45-49.  Back to cited text no. 26
    
27.
Zhang J, Guan M, Xie C, Luo X, Zhang Q, Xue Y. Increased growth factors play a role in wound healing promoted by noninvasive oxygen-ozone therapy in diabetic patients with foot ulcers. Oxid Med Cell Longev. 2014;2014:273475.  Back to cited text no. 27
    
28.
Valacchi G, Bocci V. Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. Mediators Inflamm. 1999;8:205-209.  Back to cited text no. 28
    
29.
Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol. 2003;81:355-363.  Back to cited text no. 29
    
30.
Travagli V, Zanardi I, Valacchi G, Bocci V. Ozone and ozonated oils in skin diseases: a review. Mediators Inflamm. 2010;2010:610418.  Back to cited text no. 30
    
31.
Bulynin VI, Ermakova AI, Glukhov AA, Mozhurov IP. Wound treatment using the flow of an ozonized solution under high pressure. Khirurgiia (Mosk). 1998:23-24.  Back to cited text no. 31
    
32.
Gajendrareddy PK, Sen CK, Horan MP, Marucha PT. Hyperbaric oxygen therapy ameliorates stress-impaired dermal wound healing. Brain Behav Immun. 2005;19:217-222.  Back to cited text no. 32
    
33.
Werkmeister H. Dekubitalgeschwüre und die Behandlung mit der Ozon-Unterdruckbegasung. In: Viebahn-Hänsler R, Knoch HG, eds. Ozon-Handbuch. Grundlagen. Prävention. Therapie. Landsberg: Ecomed; 2001.  Back to cited text no. 33
    
34.
Záhumenský E. Infections and diabetic foot syndrome in field practice. Vnitr Lek. 2006;52:411-416.  Back to cited text no. 34
    
35.
Fathi AM, Mawsouf MN, Viebahn-Hänsler R. Ozone Therapy in Diabetic Foot and Chronic, Nonhealing Wounds. Ozone Sci Eng. 2012;34:438-450.  Back to cited text no. 35
    
36.
Degli Agosti I, Ginelli E, Mazzacane B, et al. Effectiveness of a Short-Term Treatment of Oxygen-Ozone Therapy into Healing in a Posttraumatic Wound. Case Report Med. 2016;2016:9528572.  Back to cited text no. 36
    
37.
Bocci V. Biological and clinical effects of ozone. Has ozone therapy a future in medicine? Br J Biomed Sci. 1999;56:270-279.  Back to cited text no. 37
    
38.
Shah P, Shyam AK, Shah S. Adjuvant combined ozone therapy for extensive wound over tibia. Indian J Orthop. 2011;45:376-379.  Back to cited text no. 38
    
39.
Bialoszewski D, Kowalewski M. Superficially, longer, intermittent ozone theraphy in the treatment of the chronic, infected wounds. Ortop Traumatol Rehabil. 2003;5:652-658.  Back to cited text no. 39
    
40.
Rosul MV, Patskan BM. Ozone therapy effectiveness in patients with ulcerous lesions due to diabetes mellitus. Wiad Lek. 2016;69:7-9.  Back to cited text no. 40
    
41.
Rosul MB, Patskan BM, Nemesh, II. Microbial community in wound defects of patients with diabetic foot syndrome in practice of family doctor. Wiad Lek. 2014;67:378-380.  Back to cited text no. 41
    
42.
Martínez-Sánchez G, Al-Dalain SM, Menéndez S, et al. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol. 2005;523:151-161.  Back to cited text no. 42
    
43.
Zubarev PN, Risman BV. Ultrasonic cavitation and ozonization in treatment of patients with pyo-necrotic complications of diabetic foot syndrome. Vestn Khir Im I I Grek. 2011;170:48-53.  Back to cited text no. 43
    
44.
Uzun G, Mutluoğlu M, Karagöz H, Memiş A, Karabacak E, Ay H. Pitfalls of intralesional ozone injection in diabetic foot ulcers: a case study. J Am Coll Clin Wound Spec. 2012;4:81-83.  Back to cited text no. 44
    
45.
Steppan J, Meaders T, Muto M, Murphy KJ. A metaanalysis of the effectiveness and safety of ozone treatments for herniated lumbar discs. J Vasc Interv Radiol. 2010;21:534-548.  Back to cited text no. 45
    
46.
Re L, Malcangi G, Martinezsanchez G. Medical ozone is now ready for a scientific challenge: current status and future perspectives. Int J Ozone Ther. 2012;2:94.  Back to cited text no. 46
    
47.
Lo Giudice G, Valdi F, Gismondi M, Prosdocimo G, de Belvis V. Acute bilateral vitreo-retinal hemorrhages following oxygen-ozone therapy for lumbar disk herniation. Am J Ophthalmol. 2004;138:175-177.  Back to cited text no. 47
    
48.
Ginanneschi F, Cervelli C, Milani P, Rossi A. Ventral and dorsal root injury after oxygen-ozone therapy for lumbar disk herniation. Surg Neurol. 2006;66:619-620; discussion 620-621.  Back to cited text no. 48
    
49.
Corea F, Amici S, Murgia N, Tambasco N. A case of vertebrobasilar stroke during oxygen-ozone therapy. J Stroke Cerebrovasc Dis. 2004;13:259-261.  Back to cited text no. 49
    
50.
Bo W, Longyi C, Jian T, et al. A pyogenic discitis at C3-C4 with associated ventral epidural abscess involving C1-C4 after intradiscal oxygen-ozone chemonucleolysis: a case report. Spine (Phila Pa 1976). 2009;34:E298-304.  Back to cited text no. 50
    
51.
Gazzeri R, Galarza M, Neroni M, Esposito S, Alfieri A. Fulminating septicemia secondary to oxygen-ozone therapy for lumbar disc herniation: case report. Spine (Phila Pa 1976). 2007;32:E121-123.  Back to cited text no. 51
    
52.
Marchetti D, La Monaca G. An unexpected death during oxygen-ozone therapy. Am J Forensic Med Pathol. 2000;21:144-147.  Back to cited text no. 52
    
53.
Menendez-Cepero S. Teratogenic study of ozone. Possible indications in obstetrics and gynecology [abstract]. Proceedings of the 5Th WFOT Meeting; 2016 Nov 18-20; Mumbai, India. J Ozone Ther. 2018;2(2). doi: 10.7203/jo3t.2.2.2018.1112.  Back to cited text no. 53
    
54.
Lim JZ, Ng NS, Thomas C. Prevention and treatment of diabetic foot ulcers. J R Soc Med. 2017;110:104-109.  Back to cited text no. 54
    
55.
Volmer-Thole M, Lobmann R. Neuropathy and Diabetic Foot Syndrome. Int J Mol Sci. 2016;17.  Back to cited text no. 55
    
56.
Peter-Riesch B. The diabetic foot: the never-ending challenge. Endocr Dev. 2016;31:108-134.  Back to cited text no. 56
    
57.
Sinwar PD. The diabetic foot management - recent advance. Int J Surg. 2015;15:27-30.  Back to cited text no. 57
    
58.
Alavi A, Sibbald RG, Mayer D, et al. Diabetic foot ulcers: Part I. Pathophysiology and prevention. J Am Acad Dermatol. 2014;70:1.e1-18; quiz 19-20.  Back to cited text no. 58
    
59.
Soliman M, Rajbhandari SM. Assessing outcome of diabetic foot ulcers and multidisciplinary foot clinic. Curr Diabetes Rev. 2013;9:397-401.  Back to cited text no. 59
    
60.
Troskot N, Duvancić T, Kolić M. Diabetic foot syndrome--dermatological point of view. Acta Clin Croat. 2013;52:99-106.  Back to cited text no. 60
    
61.
Sekhar MS, Thomas RR, Unnikrishnan MK, Vijayanarayana K, Rodrigues GS. Impact of diabetic foot ulcer on health-related quality of life: A cross-sectional study. Semin Vasc Surg. 2015;28:165-171.  Back to cited text no. 61
    

Acknowledgement
The authors are thankful to Drs. Kelly Warren, Inefta Reid, Todd Miller, and Peter Brink (Department of Physiology and Biophysics, Stony Brook University School of Medicine, Stony Brook, NY, USA) for departmental support, as well as Mrs. Wendy Isser and Ms. Grace Garey (NorthportVA Medical Center Library, Northport, NY, USA) for literature retrieval.
Author contributions
RK designed, organized, and wrote the review article; designed the outline; solved queries related to scientific publications from the journals. JG performed Medline searches, aided in writing the review article and critiqued the literature. OS critiqued and applied logical reasoning to the literature. WJ critiqued and applied logical reasoning to the literature. GJ revised the article to add logical reasoning and corrected the literature. NLS formulated clinical concepts, reviewed the article, and corrected the references. SAK formulated clinical concepts, reviewed the article, and corrected the references. All authors have read and approved the manuscript provided.
Conflicts of interest
The authors have no conflicts of interest.
Copyright license agreement
The Copyright License Agreement has been signed by all authors before publication.
Plagiarism check
Checked twice by iThenticate.
Peer review
Externally peer reviewed.
Open peer reviewer
Ono Hirohisa, Nishijima Hospital, Japan.



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Classification o...
Molecular Geneti...
Diagnosis of Dia...
Applying Ozone t...
Safety of Ozone ...
Preventive Care
Conclusion
References
Article Tables

 Article Access Statistics
    Viewed414    
    Printed5    
    Emailed0    
    PDF Downloaded85    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]